Marston NA, Giugliano RP, Im K, et al. - Via a performing a systematic review and trial-level meta-regression analysis, researchers evaluated three classes of lipid-lowering treatments— fibrates, niacin, and marine-derived omega-3 fatty acids—that reduce triglyceride levels to a greater extent than LDL cholesterol. A total of 197,270 individuals from 24 trials of non-statin therapy with 25,218 major vascular events, as well as 177,088 individuals from 25 trials of statin therapy with 20,962 major vascular events were involved, for a total of 374,358 individuals and 46,180 major cardiovascular incidents. Triglyceride lowering was correlated to a lower risk of major vascular events, even subsequent to adjusting for LDL cholesterol lowering; however, the impact was attenuated when REDUCE-IT was eliminated. Moreover, the advantages of marine-derived omega-3 fatty acids, especially high-dose EPA, seemed to transcend their lipid-lowering influences.